40277-35-8

Usage

Uses

Used in Pharmaceutical Research:
2,4-dichloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine is used as a key intermediate in the synthesis of new drugs, particularly for the treatment of various diseases. Its unique chemical structure allows for the exploration of its potential in medicinal chemistry, where it can be modified to enhance its therapeutic properties or to target specific biological pathways.
Used in Agrochemical Research:
In the agrochemical industry, 2,4-dichloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine is used as a starting material for the development of new pesticides or herbicides. Its hydrophobic nature and stability contribute to its potential effectiveness in these applications, where it can be tailored to target specific pests or weeds while minimizing environmental impact.
Used in Drug Discovery:
2,4-dichloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine is employed as a lead compound in drug discovery efforts. Its complex structure provides a foundation for the design of novel therapeutic agents, with the aim of identifying new drugs with improved efficacy, safety, and selectivity for treating a range of medical conditions.

Upstream product

• 27285-09-2 2,4-Dioxo-1,2,3,4,5,6,7,8-octahydro-<1>-1-benzothieno<2,3-d>pyrimidine 
• 108354-78-5 methyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 
• 4506-71-2 ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 
• 27285-09-2 C₁₀H₁₀N₂O₂S 
• 4651-91-6 3-cyano-2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 27285-09-2 2,4-Dioxo-1,2,3,4,5,6,7,8-octahydro-<1>-1-benzothieno<2,3-d>pyrimidine 
• 81766-02-1 2-amino-3,4,5,6,7,8-hexahydro<1>benzothieno<2,3-d>pyrimidin-4-one 
• 107640-23-3 (2-Chloro-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-propyl-amine 
• 78052-14-9 2-methylthio-3,4,5,6,7,8-hexahydrobenzothieno<2,3-d>pyrimidine 
• 101323-79-9 (2-Morpholin-4-yl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-o-tolyl-amine 
• 101323-82-4 (2-Morpholin-4-yl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-m-tolyl-amine 
• 101323-81-3 (2-Morpholin-4-yl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-phenyl-amine 
• 107640-29-9 N²,N⁴-Dibenzyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine-2,4-diamine 
• 101323-85-7 N²,N⁴-Di-o-tolyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine-2,4-diamine 
• 101323-86-8 (2-Chloro-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-o-tolyl-amine 
• 101323-83-5 N²,N⁴-Di-m-tolyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine-2,4-diamine 
• 101323-88-0 (2-Chloro-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-m-tolyl-amine 
• 101323-84-6 N²,N⁴-Diphenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine-2,4-diamine 

Relevant academic research and scientific papers

SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS

Compositions and methods are provided for treating HPV infections including pre-malignant and cancers. Compounds that specifically bind to the HPV E6 protein and inactivate the protein are disclose.

Design, synthesis, and biological evaluation of novel thienopyrimidine derivatives as PI3Kα inhibitors

Three series of novel thienopyrimidine derivatives 9a-l, 15a-l, and 18a-h were designed and synthesized, and their IC50 values against four cancer cell lines HepG-2, A549, PC-3, and MCF-7 were evaluated. Most compounds show moderate cytotoxicity against the tested cancer cell lines. The most promising compound 9a showed moderate activity with IC50 values of 12.32 ± 0.96, 11.30 ± 1.19, 14.69 ± 1.32, and 9.80 ± 0.93 μM, respectively. The inhibitory activities of compounds 9a and 15a against PI3Kα and mTOR kinase were further evaluated. Compound 9a exhibited PI3Kα kinase inhibitory activity with IC50 of 9.47 ± 0.63 μM. In addition, docking studies of compounds 9a and 15a were also investigated.

IRAK INHIBITORS AND USES THEREOF

The present invention provides arylo-fused thienopyrimidine compounds, compositions thereof, and methods of using the same.

FLT3 INHIBITORS AND USES THEREOF

The present invention provides methods of using compounds of formula I: or compositions thereof for the inhibition of FLT3, and the treatment of FLT3-mediated disorders.

IRAK INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Facile and efficient cyclization of anthranilonitrile to 2,4-dichloroquinazoline by bis(trichloromethyl) carbonate and catalytic amount triphenylphosphine oxide

2,4-Dichloroquinazolines were synthesized by the cyclization of anthranilonitrile using bis(trichloromethyl) carbonate (BTC) with the aid of catalytic amount of triphenylphosphine oxide (Ph3PO) at 120 °C. This method was also applied to the syn

Cyclic Guanidines. 14. Imidazothienopyrimidin-2-one Derivatives as Blood Platelet Aggregation Inhibitors

A series of novel 1,2,3,5-tetrahydroimidazothieno-, --, and -pyrimidin-2-one derivatives has been prepared and tested for the activity of inhibiting platelet aggregation in rats in vitro and ex vivo.These compounds were synthes